Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H20ClN3.ClH |
| Molecular Weight | 326.264 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CCN(CC1=CC=C(Cl)C=C1)C2=CC=CC=N2
InChI
InChIKey=VEYWWAGBHABATA-UHFFFAOYSA-N
InChI=1S/C16H20ClN3.ClH/c1-19(2)11-12-20(16-5-3-4-10-18-16)13-14-6-8-15(17)9-7-14;/h3-10H,11-13H2,1-2H3;1H
| Molecular Formula | C16H20ClN3 |
| Molecular Weight | 289.803 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chloropyramine is an antagonist of H1 histamine receptors. It is indicated for the treatment of various forms of allergic reactions. Chloropyramine is a drug capable of (1) inhibiting the biochemical function of VEGFR-3 and FAK, (2) inhibiting proliferation of a diverse set of cancer cell types in vitro, and (3) reducing tumor growth in vivo.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2695 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | ALLERGOSAN Approved UseIn the form of solution for injection, it is used in: acute allergic reactions related to urticaria treatment (due to foods, medicines, helminthes, etc.) and insect bite; in allergic reactions of general type (anaphylactic shock, serum disease, Quincke’s edema), when the product is used as a part of the complex therapy. In the form of tablets: for treatment of allergic rhinitis, conjunctivities, hay fever, drug and food allergy, allergic reactions after insect bite. In the form of ointment or cream it is used for treatment of allergic skin reactions. |
Sample Use Guides
Composition:
One ampoule of 2 ml contains 20 mg chloropyramine hydrochloride (10 mg/ml).
One coated tablet contains 25 mg chloropyramine hydrochloride.
1 g of ointment (1%) contains 10 mg chloropyramine hydrochloride.
1 g of cream (1%) contains 10 mg chloropyramine hydrochloride.
Dosage and administration:
Parenteral administration: in severe allergic reactions 1-2 ampoules intramuscularly or intravenously.
Oral administration: adults - 25 mg (1 tabl.) 3-4 times daily (up to 150 mg, if necessary); children over 5 years: 1 tablet, 2-3 times daily.
External application: affected area should be treated once or several times a day by applying a thin layer of ointment or cream.
Route of Administration:
Other
SKN-AS and SK-N-BE(2) neuroblastoma cells were treated with varying concentrations of chloropyramine hydrochloride (C4) for 24 h and cellular viability was measured. Both cell lines demonstrated a decrease in survival that was signifi-cant at 100 μM concentration. The calculated LC50 for C4 was similar in the two cell lines at 170 μM in the SK-N-AS cell line and 144 mM in the SK-N-BE(2) cell line.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:41:09 UTC 2023
by
admin
on
Fri Dec 15 17:41:09 UTC 2023
|
| Record UNII |
FWA92Z14NN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
228-216-2
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
100000085646
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
6170-42-9
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
409949
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
DBSALT000909
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
25294
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
C97693
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
C004664
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
DTXSID9048859
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
FWA92Z14NN
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
SUB01233MIG
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | |||
|
m3434
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | Merck Index | ||
|
236457
Created by
admin on Fri Dec 15 17:41:09 UTC 2023 , Edited by admin on Fri Dec 15 17:41:09 UTC 2023
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |